# CJC-1295 / Ipamorelin: a raised floor and a sharper beat > CJC-1295 / Ipamorelin — Growth Hormone Axis research peptides | skyhighpeptides — The CJC-1295 / ipamorelin combination in the literature: two receptors, two second messengers, one supra-additive pulse — and a fixed blend that has never been through a controlled human trial. Mechanism, read-across evidence and cautions from the skyhighpeptides digest of Growth Hormone Axis research peptides. **04 · ANSWER FOUR: BOTH AT ONCE** Two peptides on two receptors, chosen because their pathways are independent. The receptor-level case for combining them is genuinely strong. The case for the blend as tested in humans does not exist, because it has not been tested. ## The short version This is not a compound. It is a pair — CJC-1295 and ipamorelin, injected together — and the reason people pair them is worth understanding, because it is a real piece of pharmacology rather than a marketing idea. The pituitary cells that make growth hormone have two separate release triggers wired to two separate internal signalling systems. CJC-1295 presses one. Ipamorelin presses the other. Pressing both is not the same as pressing one harder: when both receptors were switched on together in laboratory cells, the internal signal came out at roughly **twice** the level produced by one receptor alone [20]. Add the timing difference and the intent becomes clear. CJC-1295 with its albumin hook works for days, holding the baseline up [11]; ipamorelin works for hours, producing one sharp spike [4]. Together they are meant to give a raised floor *and* a distinct beat on top of it — the closest thing this category has to designing a hormone pattern rather than just raising a number. That is the theory, and the theory is respectable. The gap is that no controlled human trial has ever tested this fixed blend for any outcome. ## What it is The combination consists of two distinct molecules with nothing structurally in common. **CJC-1295** is a tetra-substituted analogue of hGRF(1–29)NH2. The "with DAC" form adds a C-terminal N-epsilon-maleimidopropionamide-lysine that bonds covalently to Cys34 of serum albumin for an extended half-life; the "no-DAC" form, Modified GRF (1–29), omits it and lasts on the order of thirty minutes [19]. **Ipamorelin** is a synthetic pentapeptide, Aib-His-D-2-Nal-D-Phe-Lys-NH2, and a selective agonist of GHS-R1a, the ghrelin receptor [6]. The combination circulates under a long list of names — CJC/Ipa, "GHRH + GHRP stack", CJC-1295 DAC + Ipamorelin, Mod GRF (1–29) + Ipamorelin — and those names are not interchangeable, because the DAC and no-DAC variants of the first component behave completely differently. A protocol pairing ipamorelin with no-DAC produces two short-acting signals; a protocol pairing it with DAC produces a short signal layered on a multi-day one. Those are different experiments. Neither component is approved by any regulator for any human indication. Compounding status has moved: both were added to the interim 503A Category 2 bulk-substances list in September 2023 — citing immunogenicity, peptide-impurity and limited-safety concerns, with CJC-1295 additionally flagged for cardiac effects — then removed from Category 2 in September 2024 after the nominators withdrew, with Pharmacy Compounding Advisory Committee re-evaluation scheduled for late 2024. Both are prohibited in sport at all times under WADA Section S2, and may also fall under S0 as non-approved substances. ## How it works: two receptors, two second messengers CJC-1295 binds the GHRH receptor, a class-B GPCR on pituitary somatotrophs, and raises cAMP through Gs. Ipamorelin binds GHS-R1a on the same cells and raises intracellular calcium through Gq. Because the two arms run through independent pathways, co-stimulation is expected to produce a growth-hormone pulse larger than either agent alone — supra-additive rather than merely additive — with downstream IGF-1 elevation following. The receptor-level evidence for that is direct. Co-activating the cloned growth-hormone-secretagogue receptor and the GHRH receptor in transfected HeLa cells produced a cAMP response approximately twice that of GHRH-receptor activation alone, which points to genuine cross-talk at the level of intracellular signalling rather than two effects simply summing [20]. There is a second, hypothalamic contribution as well: the ghrelin arm is understood to reduce somatostatin tone, which removes a brake at the same moment the GHRH arm applies the accelerator. For a site organised around pulsatility, this is the most conceptually complete answer of the four — and also the one whose execution is least characterised. The two halves run on incompatible clocks. CJC-1295 with DAC sustains growth-hormone and IGF-1 elevation for days after a single dose [11]; ipamorelin is largely cleared within a couple of hours, with its growth-hormone peak around 40 minutes [4]. Pairing a multi-day agent with a short-acting one means the resulting exposure pattern — the thing the whole rationale is about — is not characterised for any particular protocol. Worth stating flatly: the synergy literature that justifies the pairing studied **short, co-administered pulses** in cells and animals [20]. Chronic continuous GHRH-pathway drive from the DAC form is a different exposure profile from the one that evidence describes. ## What the research shows There is no peer-reviewed human pharmacology study of the pre-mixed CJC-1295 / ipamorelin combination. Everything below is read-across: evidence about one component, or about the wider class, applied to a pairing nobody has trialled. **The GHRH arm has genuine outcome evidence — from a different analogue.** A 2026 meta-analysis of five randomised controlled trials of tesamorelin, a GHRH analogue, found significant reductions in visceral adipose tissue (mean difference −27.71 cm²) and hepatic fat (mean difference −4.28%), increased lean body mass (+1.42 kg) and increased IGF-1, with no serious adverse events and no glucose perturbation [17]. This is the highest-quality evidence anywhere on this site that GHRH-analogue stimulation of the growth-hormone axis produces measurable body-composition change with a manageable short-term safety profile. It is also, precisely, evidence about tesamorelin — not about CJC-1295, not about ipamorelin, and not about the two together. **The class safety synthesis is reassuring and incomplete in the same sentence.** A review of growth-hormone secretagogues found them well tolerated overall, identified increased blood glucose from decreased insulin sensitivity as the chief safety concern, and concluded that long-term data on cancer incidence and mortality are still needed [18]. That is the best available safety framing for this category: favourable short-term tolerability, a real metabolic signal, unresolved long-term oncologic questions. **The pharmacokinetics of each half are known separately.** For CJC-1295 (DAC), a single subcutaneous dose raised mean plasma growth hormone 2- to 10-fold for six days or more and IGF-1 1.5- to 3-fold for 9–11 days in healthy adults, with IGF-1 staying above baseline up to 28 days after multiple doses [11]. The albumin chemistry behind that duration was established in rats, where the conjugate produced roughly a four-fold increase in growth-hormone AUC over two hours versus hGRF(1–29), with albumin-bound peptide detectable beyond 72 hours [19]. **And the receptor synergy is real but cellular** [20]. What is missing from that list is any measurement of what the combination does in a person. There is no controlled head-to-head trial comparing this pairing with sermorelin, with tesamorelin, or with exogenous growth hormone. The only combination-specific result in the corpus is preclinical: a 2026 narrative review reported that CJC-1295 with ipamorelin improved maximum tetanic tension in a murine glucocorticoid-induced muscle-loss model, while concluding that safety and dosing data remain unknown and that significant research is required before clinical recommendations can be made [7]. ## Reported effects, cautions and safety The community record for this pairing is **anecdotal, not clinical evidence** — unverified self-reports about unverified material, gathered from research-use forums and clinic write-ups, with no controls and no confirmation of what was actually administered. Deeper, more restorative sleep is the single most-cited benefit and is usually described as arriving within the first week or two, with users attributing it to the ipamorelin pulse layered on a steadier CJC-1295 background. Faster workout recovery and reduced soreness is frequently reported and described as cumulative over weeks. Increased appetite in the hours after dosing is frequently reported and attributed to the ghrelin arm — a benefit for some and unwanted for others. Gradual fat loss and a leaner look from roughly week five onward, better skin, nails and connective-tissue feel, and improved mood or energy are all reported occasionally and heavily confounded. On the adverse side, injection-site redness or itching is frequently reported; water retention and puffiness in the first month, a transient facial flush or head-rush within minutes of dosing, carpal-tunnel-like tingling in the hands, post-injection grogginess and brief lightheadedness are each reported occasionally. The reasoned safety picture, all of it class-level or single-component: **Proliferation risk is mechanistic and unstudied for this blend.** Growth hormone drives hepatic IGF-1, IGF-1 is a well-characterised mitogen, and this pairing exists specifically to amplify growth-hormone output — the CJC-1295 half raising growth hormone 2- to 10-fold for six or more days and IGF-1 for 9–11 days after a single dose [11], the ipamorelin half releasing growth hormone potently in its own right [6]. The concern about pre-existing or occult proliferative disease follows from that mechanism. It has never been tested: the fixed blend has no carcinogenicity or tumour-promotion study in any species, so the absence of a signal is the absence of a study. **Glucose is the predictable metabolic cost.** Growth hormone reduces peripheral insulin sensitivity, and the secretagogue class review identifies raised blood glucose from decreased insulin sensitivity as its chief safety concern [18]. A combination designed to increase growth-hormone output should be expected to carry that effect, and it is least predictable in anyone whose glucose handling is already impaired. No human glycemic data exist for this blend. **The mismatched clocks are themselves a safety issue.** CJC-1295 with DAC drives the GHRH pathway for days [11][19] while ipamorelin produces a short pulse and clears within hours [6]. The net growth-hormone exposure of any given protocol is therefore uncharacterised, and sustained continuous drive from the DAC form is a materially different exposure than the intermittent co-stimulation the synergy evidence describes [20]. **Fluid retention, carpal tunnel and joint pain are the mechanistically expected nuisances.** Growth-hormone excess is classically associated with sodium and water retention, soft-tissue swelling, nerve compression at the wrist and arthralgia — at the extreme, this is the acromegaly picture. The secretagogue review notes these among the class's tolerability considerations [18], and the CJC-1295 component is documented to raise growth hormone and IGF-1 substantially and for days [11]. In anyone with pre-existing heart failure or an edema-prone physiology, a sustained fluid-retaining stimulus is the relevant concern rather than a cosmetic one. **No approval, no long-term database, no quality assurance.** Neither component is approved anywhere, the fixed combination has never been studied in a controlled human trial, and the broad secretagogue review that frames these compounds as generally well tolerated is explicit that long-term and large-population safety data are lacking [18]. Research-grade peptide from unregulated suppliers carries unverified identity, purity and sterility, and the dominant community route — subcutaneous self-administration of a reconstituted powder — has no published safety or pharmacokinetic characterisation. Mis-reconstitution, contamination and injection-site complications sit entirely outside any studied protocol. One further complication that undercuts the most common reason people reach for this pairing: ipamorelin showed a growth-hormone-independent adipogenic effect in growth-hormone-intact mice, increasing body fat through leptin and appetite pathways. A simple fat-loss narrative does not survive contact with that finding. ## Where it fits in the growth hormone axis The combination is the most ambitious answer of the four and the least verified. Conceptually it is the only one that addresses both halves of the pulsatility problem at once — CJC-1295 raising the floor while preserving the rhythm [11][12], ipamorelin adding a sharp, selective beat [4][6], with a receptor-level mechanism explaining why the two together exceed the sum [20]. Set against that, it is also the only entry here that is a *protocol* rather than a studied agent. Its evidence is entirely borrowed: outcome data from a different GHRH analogue [17], safety framing from a class review [18], pharmacokinetics from each half in isolation [11][19], synergy from transfected cells [20], and one murine muscle result from a narrative review that explicitly declines to make clinical recommendations [7]. That is not a reason to dismiss it. It is a reason to describe it accurately: a mechanistically coherent idea that has not been through the process that would tell anyone whether the idea works. Read the components on their own terms — [Ipamorelin](/ipamorelin), [CJC-1295](/cjc-1295), [Sermorelin](/sermorelin) — or [compare these peptides](/compare) in a single table. --- A literature digest on the growth-hormone axis, written to keep the pulse — and the evidence behind it — in proportion; not a clinic, not a pharmacy, and not medical advice.